The Search for Cancer Biomarkers: Assessing the Distribution of INDEL Markers in Different Genetic Ancestries

Roberta B. Andrade 1,†, Giovanna C. Cavalcante 2,†, Marcos A. T. Amador 2, Fabiano Cordeiro Moreira 1, André S. Khayat 1, Paulo P. Assumpção 1, Andréa Ribeiro-dos-Santos 1,2,*, Ney P. C. Santos 1 and Sidney Santos 1,2,*.  

1 Center of Oncology Research, Graduate Program in Oncology and Medical Sciences, Federal University of Pará, Belém 66073-005, Brazil; robertaborgesandrade@hotmail.com (R.B.A.); fabiano.ufpa@gmail.com (F.C.M.); khayatas@gmail.com (A.S.K.); assumpcop@gmail.com (P.P.A.); akelyufpa@gmail.com (Â.R.-d.-S.); nptcsantos@yahoo.com.br (N.P.C.S.)  
2 Laboratory of Human and Medical Genetics, Graduate Program in Genetics and Molecular Biology, Federal University of Pará, Belém 66075-110, Brazil; giovannacavalcante@gmail.com (G.C.C.); marcosmata52@yahoo.com.br (M.A.T.A.)  
* Correspondence: sidneysantosufpa@gmail.com  
† These authors contributed equally to this work.

Abstract: Cancer is a multifactorial group of diseases, being highly incident and one of the leading causes of death worldwide. In Brazil, there is a great variation in cancer incidence and impact among the different geographic regions, partly due to the genetic heterogeneity of the population in this country, composed mainly by European (EUR), Native American (NAM), African (AFR), and Asian (ASN) ancestries. Among different populations, genetic markers commonly present diverse allelic frequencies, but in admixed populations, such as the Brazilian population, data is still limited, which is an issue that might influence cancer incidence. Therefore, we analyzed the allelic and genotypic distribution of 12 INDEL polymorphisms of interest in populations from the five Brazilian geographic regions and in populations representing EUR, NAM, AFR, and ASN, as well as tissue expression in silico. Genotypes were obtained by multiplex PCR and the statistical analyses were done using R, while data of tissue expression for each marker was extracted from GTEx portal. We highlight that all analyzed markers presented statistical differences in at least one of the population comparisons, and that we found 39 tissues to be differentially expressed depending on the genotype. Here, we point out the differences in genotype distribution and gene expression of potential biomarkers for risk of cancer development and we reinforce the importance of this type of study in populations with different genetic backgrounds.

Keywords: INDEL; cancer; genetic ancestry; Amazon; biomarkers

1. Introduction

Cancer is one of the leading causes of death worldwide [1], being considered a group of complex diseases that involve environmental, epigenetic, and genetic factors [2,3]. It is estimated that, in 2018, around 18 million new cases of cancer occurred in the world [1]. In Brazil, the National Cancer Institute (INCA) estimates that, for each year from 2020 to 2022, there were 625 thousand new cases, although there is a great variation in magnitude and in the cancer types among the different geographic regions of this country [4]. This occurs partly because Brazil has one of the most genetically heterogeneous populations in the world, composed mainly by Native American, European, and African contributions [5]. In addition, the biggest Japanese community outside Japan is in Brazil, estimated to be around 1.5 million people [6], which allows a certain degree of admixture between this population and the Brazilian population, mainly within the regions where this community is concentrated, North and Southeast of Brazil.
In the global literature, we may find several studies involving genetic markers related to cancer, mostly in case-control association studies, in which these are used to predict risk of development and/or prognosis of a certain type of cancer in different populations [7,8]. It is notable that, among different ethnic populations (also called continental populations), genetic markers commonly present diverse allelic frequencies [9]. However, in admixed populations, such as the Brazilian population, data on the distribution of this kind of markers are still limited.

In this work, we describe the allelic and genotypic distribution of 12 Insertion/Deletion (INDEL) polymorphisms, located in genes involved in important metabolic pathways associated with carcinogenesis, in populations from the five Brazilian geographic regions and in populations representing Europeans, Africans, Native Americans, and Asians. These genes and polymorphisms have been studied and associated with various types of cancer in different populations, such as bladder cancer [10], oral cancer [11], hepatocellular carcinoma [12], breast cancer [13–15], chronic lymphoblastic leukemia [16], colorectal cancer [17–21], thyroid cancer [22] and gastric cancer [23,24]. Thus, these markers were chosen based on the importance of each gene and their potential as an influence in tumor development.

The investigated markers were divided in three groups according to gene function: genomic stability and cell death (rs3834129, rs3730485, rs17878362, rs151264360, and rs3213239, respectively in \( \text{CASP8} \), \( \text{MDM2} \), \( \text{TP53} \), \( \text{TYMS} \), and \( \text{XRCC1} \) genes); biometabolism and cell energy (rs8175347, rs28892005 and a 96 pb-insertion, respectively in \( \text{UGT1A1} \), \( \text{CYP19A1} \), and \( \text{CYP2E1} \) genes); and immune response and inflammatory processes (rs3783553, rs79071878, rs28362491 and rs11267092, respectively in \( \text{IL1A} \), \( \text{IL4} \), \( \text{NFKB1} \), and \( \text{PAR1} \) genes).

2. Materials and Methods

This study included a population of 1411 non-related and cancer-free adult individuals, recruited in ten Brazilian states, in the years of 2009 and 2010, being 480 individuals from Pará (\( n = 360 \)), Amazonas (\( n = 60 \)) and Rondônia (\( n = 60 \)) representing the North region; 370 individuals from Ceará (\( n = 135 \)), Rio Grande do Norte (\( n = 175 \)), Maranhão (\( n = 8 \)) and Pernambuco (\( n = 52 \)) representing the Northeast region; 186 individuals from Goiás (\( n = 101 \)), Mato Grosso do Sul (\( n = 49 \)) and Distrito Federal (\( n = 36 \)) representing the Midwest region; 184 individuals from São Paulo representing the Southeast region; and 191 individuals from Rio Grande do Sul representing the South region. More details on the sampling approach may be found in previous studies [25,26].

In addition, we investigated a sample of 896 individuals representative of the main ethnic groups that contributed to the Brazilian population: 222 Native Americans (NAM) from nine tribes of the Brazilian Amazon (Tiriyó, Waiápi, Zoé, Urubu-Kaapor, Awa-Guajá, Parakaná, Wai Wai, Gavião, Zoró) [27]; 211 Africans (AFR) from five different countries (Angola, Mozambique, Congo Republic, Cameroon, Ivory Coast) [28]; 270 Europeans (EUR) from two different countries (Portugal and Spain) [25,29]; and 193 Asians (ASN) from Japan [30]. By using a panel of ancestry informative markers (AIM), we have previously estimated the genomic ancestry of each group [30]. Informed consent for DNA analysis was obtained from all participants. Project approval was given by the Ethics Committee of Instituto de Ciências da Saúde, Universidade Federal do Pará.

2.1. DNA Extraction and Quantification

Samples of peripheral blood were collected from all individuals of the study and the DNA extraction was performed accordingly [31]. DNA quantification was performed with the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA).

2.2. Genotyping of Investigated Polymorphisms

Polymorphisms were genotyped by a single multiplex reaction with Master Mix QIAGEN® Multiplex PCR kit (Qiagen, Hilden, Germany) and the primers are described in Table 1. PCR preparation protocol was done as described by Cavalcante et al. [32]. All polymorphisms are functional and correspond to INDEL of DNA fragments.
Multiplex PCR products were separated and analyzed by capillary electrophoresis on the ABI 3130 Genetic Analyzer instrument, using GS-500 LIZ as a pattern of molecular weight, G5 virtual filter matrix and POP7 (instrument and reagents by Thermo Fisher Scientific). Then, samples were analyzed with GeneMapper® 3.7 software (also by Thermo Fisher Scientific).

Table 1. Technical characterization of the investigated polymorphisms.

| Gene     | ID       | Size (bp) | Primers                                           | Amplicon (bp) |
|----------|----------|-----------|---------------------------------------------------|---------------|
| CASP8    | rs3834129| 6         | F-5‘CTCTTCAATGCTTCTTGAGGT3’/R-5‘CTGCATGCGAGAGCTGAATAT3’ | 249–255       |
| CYP2E1   | -        | 96        | F-5‘TGTCCTTACAGTCAGCTTTT3’/R-5‘GGGCTTTATTTTTTTGCACTTCG3’ | 397–493       |
| CYP19A1  | rs28892005| 3         | F-5‘TGATGGAGAAAAGGCATCATTAT3’/R-5‘AAAGGCAATTCATAGACAAAAA3’ | 122–125       |
| IL1A     | rs3783553| 4         | F-5‘TGTCCTAATGCTTGCTATCC3’/R-5‘ACAGTGCTCAGGATTTGCAG3’ | 230–234       |
| IL4      | rs79071878| 70 (1–3 repeats) | F-5‘AGGGGTGAGATCTGCTTATGTT3’/R-5‘CAAATCTGACATTTGAGAG3’ | 147/217/287   |
| MDM2     | rs3730485| 40        | F-5‘GGAGTGTTCCTCTCTTATGCT3’/R-5‘GGGCTCTAGAAGTCTAAATG3’ | 192–232       |
| NFKB1    | rs28362491| 4        | F-5‘TATGAGCCATGTACCTTAC3’/R-5‘TGCTCTGCTGACTTTATGAG3’ | 366–370       |
| PAR1     | rs11267092| 13       | F-5‘AAAACCTAATTTTGCGGCTG3’/R-5‘GGGCTCAAGAATCACAAGAG3’ | 265–277       |
| TP53     | rs17878362| 16       | F-5‘GGGACTGACTTTCTGCTTGT3’/R-5‘GGGCTACGTTAGGCTTGAAG3’ | 135–141       |
| TYMS     | rs151264360| 6       | F-5‘ATCCAAACGACAAATACGCAAC3’/R-5‘CTACAAATCGGTTAGGCTGAG3’ | 148–164       |
| UGT1A1   | rs8175347| 2 (5–8 repeats) | F-5‘CTCTGAAAGATCTGACTTCCGCT3’/R-5‘AGAGGTGCGCCCTCTCTAT3’ | 133/135/137/139 |
| XRCC1    | rs3213239| 4         | F-5‘GAACCCAATCCTAAAAAGTGG3’/R-5‘AGGGGAAGAGAGAGAAGAGGAGGAG3’ | 243–247       |

2.3. Data Analyses

Allelic and genotypic frequencies were obtained by direct counting. Hardy-Weinberg Equilibrium (HWE) deviations were tested in Arlequin 3.1 software [33] and corrected by Bonferroni method. Differences in genotypic frequencies among Brazilian regions and parental populations were measured by chi-squared test ($\chi^2$ test, df = 2). FDR (False Discovery Rate) method was used to correct multiple analyses. All statistical analyses were performed in the statistical package R [34]. p-Value was considered significant if equal or lower than 0.05. In addition, to infer possible influences on cancer development, we assessed the Genotype-Tissue Expression (GTEx) Portal (https://gtexportal.org/home/, accessed on 1 May 2022) [35] to obtain the expression of each variant in different tissues.

3. Results

The observed allele and genotype frequencies for the 12 markers investigated in the Brazilian population and the continental populations (AFR, NAM, EUR and ASN) are shown in Tables S1–S3; and the distribution of the genotypes is plotted in Figure 1.

When assessing HWE with correction for multiple testing for all markers in the different populations, we did not find any deviation from HWE in the admixed populations from Brazil. However, the markers in CASP8, TP53 and XRCC1 genes in Amerindian, UGT1A1 gene in African, NFKB1 gene in European, as well as MDM2 and IL4 genes in
Asian populations, presented HWE deviation, indicating the distribution of these markers in such populations is not normalized according to HWE principles.

![Genotype distribution of the markers across the studied populations. Genotype distribution of each marker in all analyzed populations: African, European, Asian, Native American and the five regions of Brazil (North, Northeast, Midwest, Southeast and South). 11, deletion/deletion; 12, deletion/insertion; 22, insertion/insertion.](image)

**Figure 1.** Genotype distribution of the markers across the studied populations. Genotype distribution of each marker in all analyzed populations: African, European, Asian, Native American and the five regions of Brazil (North, Northeast, Midwest, Southeast and South). 11, deletion/deletion; 12, deletion/insertion; 22, insertion/insertion.

We then compared the genotypic distribution of the 12 markers among continental populations and the following results should be highlighted. Regarding biometabolism and cell energy markers (in *UGT1A1*, *CYP19A1* and *CYP2E1* genes), *CYP19A1* and *UGT1A1* did not present differences among populations in most comparisons, only in EUR vs. NAM, and *CYP2E1* also did not differ in the comparisons, except for AFR vs. ASN. As for genomic stability and cell death markers (*TYMS*, *XRCC1*, *CASP8*, *MDM2* and *TP53*), *XRCC1* and *CASP8* were significantly different in all populations, except for AFR vs. EUR; *TYMS* and *TP53* only presented statistical difference in EUR vs. ASN and NAM vs. ASN comparisons, respectively; and marker *MDM2* presented differences in the comparisons between NAM and all the other groups, but not in the other comparisons. Concerning markers of immune response and inflammatory processes (*IL1A, IL1B, NFKB1* and *PAR1*), we observed significant differences for both *IL4* and *PAR1* in all comparisons; *IL1A* was different in all comparisons, but not in AFR vs. EUR; and *NFKB1* was only different in AFR vs. EUR and NAM vs. EUR. Due to the table size, *p*-values for these comparative analyses are shown in Table S4.

Moreover, we measured and analyzed δ (delta) values or mean frequencies among continental populations (Table 2). Among the investigated markers, the difference of δ values between NAM and AFR was 32%, between NAM and EUR was 23% and between EUR and AFR was 19%. In the comparisons involving ASN, an average delta value of 14% was estimated between ASN and NAM; 21% between ANS and EUR; and 26% between ASN and AFR.
Table 2. Frequency of the shortest alleles of the 12 polymorphisms in the AFR, EUR, NAM and ASN populations, and the mean difference in frequency among populations (δ values).

| Markers | EUR | ASN | AFR | NAM | EUR/ASN | AFR/ASN | NAM/ASN | EUR/AFR | EUR/NAM | AFR/NAM |
|---------|-----|-----|-----|-----|---------|---------|---------|---------|---------|---------|
| IL1A    | 0.3 | 0.69| 0.22| 0.82| 0.39    | 0.47    | 0.13    | 0.08    | 0.52    | 0.6     |
| IL4     | 0.26| 0.69| 0.58| 0.77| 0.43    | 0.11    | 0.08    | 0.03    | 0.51    | 0.19    |
| NFKB1   | 0.38| 0.40| 0.52| 0.64| 0.02    | 0.12    | 0.24    | 0.14    | 0.26    | 0.12    |
| PAR1    | 0.77| 0.96| 0.5 | 0.95| 0.19    | 0.46    | 0.01    | 0.27    | 0.18    | 0.45    |
| UGT1A  | 0.68| 0.89| 0.45| 0.70| 0.21    | 0.44    | 0.19    | 0.23    | 0.02    | 0.25    |
| CYP19A1 | 0.42| 0.3 | 0.32| 0.37| 0.12    | 0.02    | 0.07    | 0.1     | 0.06    | 0.05    |
| CYP2E1  | 0.94| 0.8 | 0.83| 0.95| 0.14    | 0.03    | 0.15    | 0.11    | 0.01    | 0.12    |
| CASP8   | 0.47| 0.18| 0.5 | 0.23| 0.29    | 0.32    | 0.05    | 0.03    | 0.24    | 0.27    |
| TYMS    | 0.36| 0.65| 0.58| 0.21| 0.29    | 0.07    | 0.44    | 0.22    | 0.15    | 0.37    |
| XRCC1   | 0.33| 0.1 | 0.83| 0.02| 0.23    | 0.73    | 0.08    | 0.5     | 0.31    | 0.81    |
| MDM2    | 0.38| 0.33| 0.33| 0.04| 0.05    | 0.00    | 0.29    | 0.05    | 0.34    | 0.29    |
| TP53    | 0.82| 0.99| 0.62| 0.98| 0.17    | 0.37    | 0.01    | 0.2     | 0.16    | 0.36    |
| Average |     |     |     |     | 0.21    | 0.26    | 0.14    | 0.19    | 0.23    | 0.32    |

In the comparison of geographic regions, the marker in IL4 was significantly different between North and the other populations of Brazil. Additionally, distribution of the marker in IL1A was significantly different between North and the regions South, Southeast, and Northeast, and between Midwest and South. As for the polymorphism in NFKB1, it showed statistically significant difference between North and regions South and Southeast, but it was similar in all other comparisons.

Furthermore, in the GTEx analysis—performed to infer possible influences on cancer development, 39 tissues were found to be differentially expressed depending on the genotype in six of the 12 variants here investigated (Table 3). The variant that was differentially expressed in the highest number of tissues was rs3213239 (XRCC1), 30 tissues; followed by rs3834129 (CASP8), 15 tissues; rs3783553 (IL1A) and rs28362491 (NFKB1), six tissues each; rs151264360 (TYMS), three tissues; and rs11575899 (CYP19A1), two tissues.

Table 3. Differentially expressed variants in diverse tissues from GTEx. NES, Normalized Effect Size.
| Gene  | Variant ID | p-Value   | NES   | Tissue                                      |
|-------|------------|-----------|-------|---------------------------------------------|
|       |            |           |       | Skin-Not Sun Exposed (Suprapubic)           |
| IL1A  | rs3783553  | $3.9 \times 10^{-14}$ | 0.35  | Skin-Sun Exposed (Lower leg)                |
|       |            | $2.6 \times 10^{-11}$ | 0.30  | Spleen                                      |
|       |            | $2.0 \times 10^{-7}$  | 0.37  | Testis                                      |
|       |            | 0.0000018  | 0.19  | Esophagus-Mucosa                            |
|       |            | 0.000028   | 0.16  | Thyroid                                     |
|       |            | 0.00016    | 0.19  |                                             |
|       |            | $9.9 \times 10^{-14}$ | 0.15  | Muscle-Skeletal                             |
| NFKB1 | rs28362491 | $6.0 \times 10^{-8}$  | 0.12  | Cells-Cultured fibroblasts                  |
|       |            | $2.4 \times 10^{-7}$  | 82    | Whole Blood                                 |
|       |            | 0.0000018  | −0.12 | Testis                                      |
|       |            | 0.000099   | −0.12 | Heart-Atrial Appendage                      |
|       |            | 0.00021    | −77   | Skin-Not Sun Exposed (Suprapubic)           |
|       |            | $6.6 \times 10^{-34}$ | 0.66  | Esophagus-Muscularis                        |
| TYMS  | rs151264360| $1.7 \times 10^{-22}$ | −0.28 | Testis                                      |
|       |            | $8.1 \times 10^{-17}$ | 0.53  | Esophagus-Gastroesophageal Junction         |
|       |            | $4.4 \times 10^{-45}$ | −0.43 | Thyroid                                     |
|       |            | $5.4 \times 10^{-42}$ | −0.53 | Pancreas                                    |
|       |            | $2.0 \times 10^{-26}$ | −0.49 | Testis                                      |
|       |            | $2.0 \times 10^{-24}$ | −0.58 | Adrenal Gland                               |
|       |            | $3.8 \times 10^{-19}$ | −0.23 | Muscle-Skeletal                             |
|       |            | $6.3 \times 10^{-15}$ | −0.32 | Pituitary                                   |
|       |            | $4.1 \times 10^{-13}$ | 0.20  | Nerve-Tibial                                |
|       |            | $4.2 \times 10^{-13}$ | −0.46 | Brain-Hypothalamus                          |
|       |            | $8.7 \times 10^{-11}$ | −0.23 | Colon-Sigmoid                               |
|       |            | $1.5 \times 10^{-10}$ | −0.54 | Brain-Anterior cingulate cortex (BA24)       |
|       |            | $4.8 \times 10^{-10}$ | −0.38 | Brain-Caudate (basal ganglia)               |
|       |            | $6.8 \times 10^{-10}$ | −0.23 | Stomach                                     |
|       |            | $1.1 \times 10^{-9}$  | −0.34 | Ovary                                       |
|       |            | $1.7 \times 10^{-9}$  | −0.24 | Heart-Left Ventricle                        |
|       |            | $1.2 \times 10^{-9}$  | −0.41 | Brain-Hippocampus                           |
|       |            | $2.0 \times 10^{-8}$  | −0.33 | Brain-Nucleus accumbens (basal ganglia)      |
|       |            | $3.7 \times 10^{-8}$  | −0.28 | Liver                                       |
|       |            | $3.8 \times 10^{-8}$  | −0.14 | Colon-Transverse                            |
|       |            | $1.7 \times 10^{-7}$  | −0.29 | Brain-Frontal Cortex (BA9)                  |
|       |            | $1.9 \times 10^{-7}$  | −0.29 | Brain-Cortex                                |
|       |            | $2.0 \times 10^{-7}$  | −0.48 | Brain-Amygdala                              |
|       |            | $4.5 \times 10^{-7}$  | −0.15 | Esophagus-Mucosa                            |
|       |            | 0.0000022   | −0.40 | Minor Salivary Gland                        |
|       |            | 0.0000028   | −0.55 | Brain-Substantia nigra                      |
|       |            | 0.0000045   | −0.30 | Brain-Putamen (basal ganglia)               |
|       |            | 0.000011    | −84   | Whole Blood                                 |
|       |            | 0.000018    | −78   | Cells-Cultured fibroblasts                  |
|       |            | 0.000031    | −24   | Prostate                                    |
|       |            | 0.000056    | −15   | Heart-Atrial Appendage                      |
|       |            | 0.00012     | −94   | Artery-Tibial                               |

Of all the found tissues, 12 seem to be regulated by more than one of the studied variants: cells—cultured fibroblasts (variants in CASP8, NFKB1, XRCC1), esophagus—mucosa (CASP8, IL1A, XRCC1), heart—atrial appendage (NFKB1, XRCC1), muscle—skeletal (CASP8, NFKB1, XRCC1), nerve—tibial (CASP8, XRCC1), pituitary gland (CASP8, XRCC1), skin—not sun exposed (NSE, suprapubic; CASP8, CYP19A1, IL1A, NFKB1), skin—sun exposed (SE, lower leg; CASP8, CYP19A1, IL1A), spleen (CASP8, IL1A), testis (IL1A, NFKB1, TYMS, XRCC1), thyroid (CASP8, IL1A, XRCC1) and whole blood (NFKB1, XRCC1).
4. Discussion

This study aimed to investigate and describe the frequencies of markers of interest (located in genes involved in important metabolic pathways associated with carcinogenesis) in populations from the five geographic populations of Brazil and in populations representing European, African, Native American, and Asian ancestries. These markers were divided according to gene functions.

In a previous study [5], the description of the group of markers of immune response and inflammatory processes was performed in the same populations investigated here, except for the Asian population. Regarding this group of markers, in addition to the results presented in that paper, it is possible to highlight that ASN population was different from all other continental populations for the investigated markers in IL1A, IL4 and PAR1. As for the marker in NFKB1, it only differed between AFR and EUR and between NAM and EUR.

In the comparisons of geographic regions, marker IL4 was significantly different between North and the other Brazilian populations. Besides that, our analysis also showed the distribution of the IL1A marker with statistical differences between North and the South, Southeast and Northeast regions, as well as between Midwest and South regions. The polymorphism in NFKB1 was also significantly different between North and the regions South and Southeast. All other distributions of this group of markers were similar among these regions.

Regarding the investigated variants in genes of biometabolism and cell energy, not many studies can be currently found analyzing their distribution in populations of different genetic ancestries. However, a study by Fritsche et al. [36] compared genotypes of the 96-bp INDEL in CYP2E1 gene in samples from individuals with African (African-American), European (European-American) and Asian (Taiwanese) genetic backgrounds and observed statistically significant differences between Europeans and Asians and between Europeans and Africans, but none between Asians and Africans, which corroborates our findings here. Concerning variant rs8175347 in UGT1A1 gene, allele frequency of this variant has been reported as different when compared in groups of European, African, and Asian (including Japanese) ancestries [37]. No studies were found with the rs28892005 variant in CYP19A1.

As for variants in the group of genomic stability and cell death, there are some papers discussing their distribution in different populations in the global literature. For instance, a previous study by our research group compared the allele distribution of rs17878362 in TP53 gene in populations of European, African, and Asian ancestry from 1000 genomes database [9], as well as a population from Northern Brazil, and observed statistical differences in all comparisons, with the exception of the one between Northern Brazil and European populations, which could be expected given the high contribution of European ancestry in this region [38]. However, it is notable that these frequencies significantly vary among different genetic backgrounds.

Similarly, the variant rs3730485 (also known as del1518) in MDM2 gene has been investigated in different populations, particularly in connection with cancer development. For example, two independent studies involving different types of cancer in Chinese cohorts have reported a frequency of 30% of DEL allele in both groups of controls [12,39]. The study by Gansmo et al. [39] also investigated this variant in other populations, indicating the presence of the same allele in 38% and 42% in the African American and the Norwegian controls, respectively. Here, we found this allele in 33%, 38% and 33% of the African, European, and Asian groups, respectively, which seem to be close to the corresponding frequencies in these previous reports. To the best of our knowledge, this is the first study investigating this variant in NAM populations from the Brazilian Amazon.

Variant rs151264360 in TYMS gene has also been widely studied regarding cancer treatment in different regions. In this context, it has been associated with response to chemotherapy for colorectal cancer in a Mexican cohort, highlighting the importance of TYMS to cancer treatment in Latin American populations [40]. In that study, DEL allele was present in 33.0% of the participants, which was similar to the frequency of this allele in a study carried in a Slovak population (37.5%) [41]. A study by Summers et al. [42] reported
a significant difference in the distribution of rs151264360 between African-Americans (DEL 53.75%) and Europeans (DEL 33.3%). These frequencies are like the ones observed here for African (DEL 58.0%) and European (DEL 36.0%) ancestries, which also showed significant differences.

Likewise, polymorphism rs3834129 in CASP8 gene has been broadly studied regarding cancer, particularly cancer development. For instance, in a study by Pardini et al. [43], DEL allele of this variant was suggested as a protective effect to colorectal cancer in the multiple populations investigated, mostly from European countries. In these populations, the presence of DEL allele ranged from 45% to 52%. In addition, two independent studies investigating the distribution of this polymorphism in British cohorts in association to different diseases have reported the presence of DEL allele as 50% in the controls [44,45]. Similarly, a study by Chatterjee et al. [46] investigated the association of this marker with HPV infection and cervical cancer in South Africa and showed the presence of DEL allele in around 52% of the controls. Here, we found this allele in 50% and 47% of the African and European groups, respectively, which are also similar frequencies and corroborate these studies.

On the other hand, there are not many studies with the variant rs3213239 (XRCC1 gene) in the specialized literature. Two studies by our research group have investigated this variant regarding cancer susceptibility in Northern Brazil, reporting association with acute lymphoblastic leukemia (ALL) [47], but not with gastric cancer or colorectal cancer [32]. Curiously, in the study by Carvalho et al. [47], not only the DEL/DEL genotype of this variant was associated with ALL, but also the genetic ancestry: NAM and EUR ancestries were associated with increased and decreased risk of developing ALL, respectively, highlighting the importance of investigating this variant in different populations.

Moreover, in the GTEx analysis, it is notable that the studied variants in CASP8 and XRCC1 appeared in most of the tissues showing more than one differentially expressed gene, nine each, of which six presented both markers: (i) cells—cultured fibroblasts, (ii) esophagus—mucosa, (iii) muscle—skeletal, (iv) nerve—tibial, (v) pituitary gland and (vi) thyroid. This suggests that these tissues are likely to be regulated by the variants in such genes, which are related to genomic stability and cell death.

Even though we did not find any works involving both CASP8 and XRCC1 and such tissues, there are a few studies in the global literature on the possible association of these genes and the development of different types of cancer, such as lung adenocarcinoma, breast cancer, gallbladder cancer, acute lymphoblastic leukemia, as well as gastric and colorectal cancers [32,47–52].

It is also notable that both skin tissues (SE and NSE) presented differential expression in CASP8, CYP19A1 and IL1A and that NSE skin also presented this difference for NFKB1. This finding suggests a possible influence of this variant and gene on skin cancer development and reinforces previous studies that have reported the association of INS/INS genotype of this variant in NFKB1 with an increased risk of developing melanoma in a Swedish and in a Brazilian population [53,54].

In addition to NSE skin, testis tissue also presented four differentially expressed variants (in IL1A, NFKB1, TYMS and XRCC1 genes), the highest number of variants per tissue in this analysis. No studies were found about these specific variants in testis or these genes in testicular cancer, but the role of IL1A, NFKB1 and XRCC1 have been reported in Sertoli cells and other essential factors for spermatogenesis [55–60]. Hence, given their importance in testis function, these genes might also be involved in carcinogenesis in this tissue.

In summary, here we thoroughly analyzed the distribution of 12 polymorphisms in diverse populations (groups from European, African, Native American, and Asian populations, as well as groups from the five admixed Brazilian geographical regions) and tissue expression. All analyzed markers presented statistical differences in at least one of the population comparisons, and we found 39 tissues to be differentially expressed depending on the genotype, suggesting these markers might play a role in cancer distribution in
different populations. Thus, we recommend future studies with larger cohorts to explore these novel observations, as this was the first study to investigate some of these markers in these populations. Based on our findings, we point out some potential biomarkers for risk of cancer development and we highlight the importance of this type of study in populations with different genetic backgrounds.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cimb44050154/s1, Table S1. Allelic and genotypic frequencies of markers in Biometabolism and Cell Energy group. Table S2. Allelic and genotypic frequencies of markers in Genomic Stability and Cell Death group. Table S3. Allelic and genotypic frequencies of markers in Immune Response and Inflammatory Processes group. Table S4. \( p \)-Values of the comparative analyses of frequencies among all populations for each marker.

**Author Contributions:** Conceptualization: N.P.C.S. and S.S.; Data curation: R.B.A., G.C.C. and M.A.T.A.; Formal analysis: F.C.M.; Funding acquisition: A.S.K., P.P.A. and Â.R.-d.-S.; Investigation: R.B.A., G.C.C. and M.A.T.A.; Methodology: N.P.C.S. and S.S.; Resources: A.S.K., P.P.A. and Â.R.-d.-S.; Supervision: N.P.C.S. and S.S.; Writing—Original draft preparation: R.B.A. and G.C.C.; Writing—Review & editing: R.B.A. and G.C.C. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by CNPq (Conselho Nacional do Desenvolvimento Científico e Tecnológico), CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), H YDRO/UFFA/FADESP (Fundação Amparo e Desenvolvimento da Pesquisa) and PROPESP (Pró-Reitoria de Pesquisa da Universidade Federal do Pará). It is part of Rede de Pesquisa em Genômica Populacional Humana (Biocomputacional—Protocol no. 3381/2013/CAPES).

**Institutional Review Board Statement:** The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Instituto de Ciências da Saúde, Universidade Federal do Pará.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available within the article or supplementary material.

**Acknowledgments:** In this section, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Globocan Cancer Today. Available online: http://gco.iarc.fr/today/home (accessed on 6 March 2019).
2. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The next Generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
3. Giampazolias, E.; Tait, S.W.G. Mitochondria and the Hallmarks of Cancer. FEBS J. 2016, 283, 803–814. [CrossRef] [PubMed]
4. INCA. Estimativa 2020: Incidência de Câncer No Brasil | INCA—Instituto Nacional de Câncer. Available online: https://www.inca.gov.br/publicacoes/livros/estimativa-2020-incidencia-de-cancer-no-brasil (accessed on 17 October 2020).
5. Amador, M.A.T.; Cavalcante, G.C.; Santos, N.P.C.; Gusmão, L.; Guerreiro, J.F.; Ribeiro-dos-Santos, Â.; Santos, S. Distribution of Allelic and Genotypic Frequencies of IL1A, IL4, NFKB1 and PAR1 Variants in Native American, African, European and Brazilian Populations. BMC Res. Notes 2016, 9, 101. [CrossRef] [PubMed]
6. Suarez-Kurtz, G. Pharmacogenetics in the Brazilian Population. Front. Pharm. 2010, 1, 118. [CrossRef]
7. Yuan, F.; Sun, R.; Li, L.; Jin, B.; Wang, Y.; Liang, Y.; Che, G.; Gao, L.; Zhang, L. A Functional Variant Rs353292 in the Flanking Region of MiR-143/145 Contributes to the Risk of Colorectal Cancer. Sci. Rep. 2016, 6, 30195. [CrossRef]
8. Wang, C.; Zhao, H.; Zhao, X.; Wan, J.; Wang, D.; Bi, W.; Jiang, X.; Gao, Y. Association between an Insertion/Deletion Polymorphism within 3’UTR of SGSM3 and Risk of Hepatocellular Carcinoma. Tumour Biol. 2014, 35, 295–301. [CrossRef]
9. 1000 Genomes Project Consortium; Auton, A.; Brooks, L.D.; Durbin, R.M.; Garrison, E.P.; Kang, H.M.; Korbel, J.O.; Marchini, J.L.; McCarthy, S.; McVean, G.A.; et al. A Global Reference for Human Genetic Variation. Nature 2015, 526, 68–74. [CrossRef]
10. Abhirwar, D.; Kesarwani, P.; Manchanda, P.K.; Mandhani, A.; Mittal, R.D. Anti- and Proinflammatory Cytokine Gene Polymorphism and Genetic predisposition: Association with Smoking, Tumor Stage and Grade, and Bacillus Calmette-Guérin Immunotherapy in Bladder Cancer. Cancer Genet. Cytogenet. 2008, 184, 1–8. [CrossRef]

11. Yang, C.-M.; Chen, H.-C.; Hou, Y.-Y.; Lee, M.-C.; Liou, H.-H.; Huang, S.-J.; Yen, L.-M.; Eng, D.-M.; Hsieh, Y.-D.; Ger, L.-P. A High IL-4 Production Diploidyte Is Associated with an Increased Risk but Better Prognosis of Oral and Pharyngeal carcinomas. Arch. Oral Biol. 2014, 59, 35–46. [CrossRef]

12. Dong, D.; Gao, X.; Zhu, Z.; Yu, Q.; Bian, S.; Gao, Y. A 40-Bp Insertion/Deletion Polymorphism in the Constitutive Promoter of MDM2 Confers Risk for Hepatocellular carcinoma in a Chinese Population. Gene 2012, 497, 66–70. [CrossRef]

13. Zhang, Y.J.; Zhong, X.P.; Chen, Y.; Liu, S.R.; Wu, G.; Liu, Y.F. Association between CASP-8 Gene Polymorphisms and Cancer Risk in Some Asian Population Based on a HuGE Review and Meta-Analysis. Genet. Mol. Res. 2013, 12, 6466–6476. [CrossRef] [PubMed]

14. Ramalhinho, A.C.M.; Fonseca-Moutinho, J.A.; Breitenfeld Granadeiro, L.A.T.G. Positive Association of Polymorphisms in Estrogen Biosynthesis Gene, CYP19A1, and Metabolism, GST, in Breast Cancer Susceptibility. DNA Cell Biol. 2012, 31, 1100–1106. [CrossRef] [PubMed]

15. Kuhlmann, J.D.; Bankfalvi, A.; Schmid, K.W.; Callies, R.; Kimmig, R.; Wimberger, P.; Siffert, W.; Bachmann, H.S. Prognostic relevance of Caspase 8 -652 6N InDel and Asp502His Polymorphisms for Breast Cancer. BMC Cancer 2016, 16, 618. [CrossRef] [PubMed]

16. Karakosta, M.; Kalotychou, V.; Pantelias, G.; Manola, K.N. UGT1A1*28 Polymorphism in Chronic Lymphocytic leukemia: The First Investigation of the Polymorphism in Disease Susceptibility and Its Specific Cytogenetic Abnormalities. Acta Haematol. 2014, 132, 59–67. [CrossRef]

17. Bajro, M.H.; Josifovski, T.; Panovski, M.; Nestorovska, A.K.; Matevska, N.; Petrusevska, N.; Dimovski, A.J. Promoter Length Polymorphism in UGT1A1 and the Risk of Sporadic colorectal Cancer. Cancer Genet. 2012, 205, 163–167. [CrossRef] [PubMed]

18. Jiang, O.; Zhou, R.; Wu, D.; Liu, Y.; Wu, W.; Cheng, N. CYP2E1 Polymorphisms and colorectal Cancer Risk: A HuGE Systematic Review and Meta-Analysis. Tumor Biol. 2013, 34, 1215–1224. [CrossRef]

19. Jirasková, A.; Novotný, J.; Vodicka, P.; Pardini, B.; Naccarati, A.; Schwertner, H.A.; Hubáček, J.A.; Puncchářová, L.; Šmerhovský, Z.; et al. Association of Serum Bilirubin and Promoter Variations in HMOX1 and UGT1A1 Genes with Prostate Colorectal Cancer. Int. J. Cancer 2012, 131, 1549–1555. [CrossRef]

20. Morita, M.; Le Marchand, L.; Kono, S.; Yin, G.; Toyomura, K.; Nagano, J.; Mizoue, T.; Mibu, R.; Tanaka, M.; Kakeji, Y.; et al. Genetic Polymorphisms of CYP2E1 and Risk of Colorectal Cancer: The Fukuoka colorectal cancer Study. Cancer Epidemiol. Biomark. Prev. 2009, 18, 235–241. [CrossRef] [PubMed]

21. Silva, T.D.; Felipe, A.V.; Pimenta, C.A.; Barão, K.; Forones, N.M. CYP2E1 Polymorphisms and colorectal Cancer Risk: A HuGE Systematic Review and Meta-Analysis. Genet. Mol. Res. 2012, 11, 3138–3145. [CrossRef] [PubMed]

22. Santoro, A.B.; Vargens, D.D.; Barros Filho, M.D.; Bulzico, D.A.; Kowalski, L.P.; Meirelles, R.M.R.; Paula, D.P.; Neves, R.R.S.; Pessoa, C.N.; Struchine, C.J.; et al. effect of UGT1A1, UGT1A3, DIO1 and DIO2 Polymorphisms on L-Thyroxine dosages required for TSH suppression in patients with differentiated thyroid cancer. Br. J. Clin. Pharmac. 2014, 78, 1067–1075. [CrossRef]

23. Fujimoto, D.; Hirono, Y.; Goi, T.; Katayama, K.; Matsukawa, S.; Yamaguchi, A. The activation of Proteinase-Activated Receptor-1 (PAR1) Promotes Gastric Cancer cell alteration of Cellular morphology related to Cell motility and Invasion. Int. J. Oncol. 2013, 42, 565–573. [CrossRef] [PubMed]

24. Qiao, W.; Wang, T.; Zhang, L.; Tang, Q.; Wang, D.; Sun, H. Association study of single nucleotide polymorphisms in XRCC1 Gene with the Risk of Gastric Cancer in Chinese population. Int. J. Biol. Sci. 2013, 9, 753–758. [CrossRef] [PubMed]

25. Santos, N.P.C.; Ribeiro-Rodrigues, E.M.; Ribeiro-dos-Santos, A.K.C.; Pereira, R.; Gusmão, L.; Amorim, A.; Guerreiro, J.F.; Zago, M.A.; Matte, C.; Hutz, M.H.; et al. Assessing Individual Interethnic admixture and Population Substructure Using a 48-Insertion-Deletion (INSEL) Ancestry-Informative Marker (AIM) Panel. Hum. Mutat. 2010, 31, 184–190. [CrossRef] [PubMed]

26. Ramos, B.R.D.A.; Mendes, N.D.; Tanikawa, A.A.; dos Santos, M.A.T.; dos Santos, S.E.B.; Castelli, E.C.; Witkin, S.; da Silva, M.G. Assessing Individual Interethnic admixture and Population Substructure Using a 48-Insertion-Deletion (INSEL) Ancestry-Informative Marker (AIM) Panel. DNA Cell Biol. 2010, 29, 753–758. [CrossRef] [PubMed]

27. Ribeiro-Rodrigues, E.M.; Palha, T.D.J.B.F.; Bittencourt, E.A.; Ribeiro-Dos-Santos, A.; Santos, S. Extensive Survey of 12 X-STRs Reveals Genetic Heterogeneity among Brazilian Populations. Int. J. Leg. Med. 2011, 125, 445–452. [CrossRef] [PubMed]

28. Silva, W.A.; Bortolini, M.C.; Schneider, M.P.C.; Marrero, A.; Elion, J.; Krishnamoorthy, R.; Zago, M.A. MtDNA Haplogroup Analysis of Black Brazilian and Sub-Saharan Populations: Implications for the Atlantic Slave Trade. Hum. Biol. 2006, 78, 29–41. [CrossRef] [PubMed]

29. Palha, T.; Gusmão, L.; Ribeiro-Rodrigues, E.; Guerreiro, J.F.; Ribeiro-dos-Santos, A.; Santos, S. Disclosing the Genetic Structure of Brazil through Analysis of Male lineages with Highly Discriminating Haplotypes. PLoS ONE 2012, 7, e40007. [CrossRef]

30. Andrade, R.B.; Amador, M.A.T.; Cavalcante, G.C.; Leitão, L.P.C.; Fernandes, M.R.; Modesto, A.A.C.; Moreira, F.C.; Khayat, A.S.; Assumpção, P.P.; Ribeiro-dos-Santos, A.; et al. Estimating Asian contribution to the Brazilian population: A New application of a Validated set of 61 Ancestry Informative markers. G3 Genes Genomes Genet. 2018, 8, 3577–3582. [CrossRef]
31. Sambrook, J.; Fritsch, E.F.; Maniatis, T. Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Long Island, NY, USA, 1989.

32. Cavalcante, G.C.; Amador, M.A.; Ribeiro Dos Santos, A.M.; Carvalho, D.C.; Andrade, R.B.; Pereira, E.E.; Fernandes, M.R.; Costa, D.F.; Santos, N.P.; Assumpção, P.P.; et al. Analysis of 12 Variants in the Development of Gastric and Colorectal Cancers. World J. Gastroenterol. 2017, 23, 8533–8543. [CrossRef]

33. Excoffier, L.; Lischer, H.E.L. Arlequin Suite Ver 3.5: A New Series of Programs to Perform Population Genetics Analyses under Linux and Windows. Mol. Ecol. Resour. 2010, 10, 564–567. [CrossRef]

34. R Core Team. R: A Language and Environment for Statistical Computing; R Core Team: Vienna, Austria, 2014.

35. GTEx Consortium. The Genotype-Tissue Expression (GTEx) Project. Nat. Genet. 2013, 45, 580–585. [CrossRef] [PubMed]

36. Fritsche, E.; Pittman, G.S.; Bell, D.A. Localization, Sequence Analysis, and Ethnic Distribution of a 96-Bp Insertion in the Promoter of the Human CYP2E1 Gene. Mutat. Res. 2000, 432, 1–5. [CrossRef]

37. Shin, H.J.; Kim, J.Y.; Cheong, H.S.; Na, H.S.; Shin, H.D.; Chung, M.W. Functional Study of Haplotypes in UGT1A1 Promoter to Find a Novel Genetic Variant Leading to Reduced Gene Expression. Drug Monit. 2015, 37, 369–374. [CrossRef] [PubMed]

38. Cavalcante, G.C.; Ribeiro-Dos-Santos, A.M.; Carvalho, D.C.D.; Silva, E.M.D.; Assumpção, P.P.D.; Ribeiro-Dos-Santos, A.; Santos, S. Investigation of Potentially Deleterious Alleles for Response to Cancer Treatment with 5-Fluouracil. Anticancer Res. 2015, 7, 6971–6977.

39. Gansmo, L.B.; Vatten, L.; Romundstad, P.; Hveem, K.; Ryan, B.M.; Harris, C.C.; Knappskog, S.; Lønning, P.E. Associations between the MDM2 Promoter P1 Polymorphism Del1518 (Rs3730485) and Incidence of Cancer of the Breast, Lung, Colon and Prostate. Oncotarget 2016, 7, 28637–28646. [CrossRef] [PubMed]

40. Castro-Rojas, C.A.; Espanzar-Mota, A.R.; Hernandez-Cabrera, E.; Romero-Diaz, V.J.; Gonzalez-Guerrero, J.F.; Maldonado-Garza, H.; Garcia-Gonzalez, I.S.; Buenaventura-Cisneros, S.; Sanchez-Lopez, J.V.; Ortiz-Lopez, R.; et al. Thymidylate Synthase Gene Variants as Predictors of Clinical Response and Toxicity to Fluoropyrimidine-Based Chemotherapy for Colorectal Cancer. Drug Metab. Pers. 2017, 32, 209–218. [CrossRef]

41. Pastorakova, A.; Chaudogova, D.; Chandoga, J.; Luha, J.; Bohmer, D.; Malova, J.; Braxatorisova, T.; Juhosova, M.; Reznakova, S.; Petrovic, R. Distribution of the Most Common Polymorphisms in TYMS Gene in Slavic Population of Central Europe. Neoplasma 2017, 64, 962–970. [CrossRef]

42. Summers, C.M.; Cucchiara, A.J.; Nackos, E.; Hammons, A.L.; Mohr, E.; Whitehead, A.S.; Von Feldt, J.M. Functional Polymorphisms of Folate-Metabolizing Enzymes in Relation to Homocysteine Concentrations in Systemic Lupus Erythematosus. J. Rheumatol. 2008, 35, 2179–2186. [CrossRef]

43. Pardini, B.; Verderio, P.; Pizzamiglio, S.; Nici, C.; Maiorana, M.V.; Naccarati, A.; Vodickova, L.; Vymetalkova, V.; Veneroni, S.; Daidone, M.G.; et al. Association between CASP8 –652 6N Del Polymorphism (Rs3834129) and Colorectal Cancer Risk: Results from a Multi-Centric Study. PLoS ONE 2014, 9, e85538. [CrossRef]

44. Pittman, A.M.; Broderick, P.; Sullivan, K.; Fielding, S.; Webb, E.; Penegar, S.; Tomlinson, I.; Houlston, R.S. CASP8 Variants D302H and –652 6N Ins/Del Do Not Influence the Risk of Colorectal Cancer in the United Kingdom Population. Br. J. Cancer 2008, 98, 1434–1436. [CrossRef]

45. Brown, K.L.; Seale, K.B.; El Khoury, L.Y.; Posthumus, M.; Ribbons, W.J.; Raleigh, S.M.; Collins, M.; September, A.V. Polymorphisms Types and Abnormal Cytology but Not with Cervical Cancer. J. Med. Virol. 2011, 83, 630–636. [CrossRef] [PubMed]

46. Chatterjee, K.; Williamson, A.-L.; Hoffman, M.; Dandara, C. CASP8 Promoter Polymorphism Is Associated with High-Risk HPV Types and Abnormal Cytology but Not with Cervical Cancer. J. Med. Virol. 2011, 83, 630–636. [CrossRef] [PubMed]

47. Cavalcante, G.C.; Wanderley, A.V.; Andrade, R.B.; Pereira, E.E.; Fernandes, M.R.; Assumpção, P.P.; et al. Association between CASP8 –652 6N Del Polymorphism (Rs3834129) and Colorectal Cancer Risk: Results from a Multi-Centric Study. PLoS ONE 2014, 9, e85538. [CrossRef]

48. Pittman, A.M.; Broderick, P.; Sullivan, K.; Fielding, S.; Webb, E.; Penegar, S.; Tomlinson, I.; Houlston, R.S. CASP8 Variants D302H and –652 6N Ins/Del Do Not Influence the Risk of Colorectal Cancer in the United Kingdom Population. Br. J. Cancer 2008, 98, 1434–1436. [CrossRef]

49. Brown, K.L.; Seale, K.B.; El Khoury, L.Y.; Posthumus, M.; Ribbons, W.J.; Raleigh, S.M.; Collins, M.; September, A.V. Polymorphisms within the COL5A1 Gene and Regulators of the Extracellular Matrix Modify the Risk of Achilles Tendon Pathology in a British Case-Control Study. J. Sports Sci. 2015, 33, 1475–1483. [CrossRef] [PubMed]

50. Chatterjee, K.; Williamson, A.-L.; Hoffman, M.; Dandara, C. CASP8 Promoter Polymorphism Is Associated with High-Risk HPV Types and Abnormal Cytology but Not with Cervical Cancer. J. Med. Virol. 2011, 83, 630–636. [CrossRef] [PubMed]

51. Marques, D.; Ferreira-Costa, L.; Ferreira-Costa, L.L.; da Silva Correa, R.; Borges, A.M.P.; Ito, F.R.; de Oliveira Ramos, C.C.; Bortolin, R.H.; Luchessi, A.D.; Ribeiro-Dos-Santos, A.; et al. Association of Insertion-Deletions Polymorphisms with Colorectal Cancer Risk and Clinical Features. World J. Gastroenterol. 2017, 23, 6854–6867. [CrossRef]

52. Catanà, A.; Pop, M.; Hincu, B.D.; Pop, I.V.; Petrișor, F.M.; Porojan, M.D.; Popp, R.A. The XRCC1 Arg194Trp Polymorphism Is Significantly Associated with Lung Adenocarcinoma: A Case-Control Study in an Eastern European Caucasian Group. Onco Targets 2015, 8, 3533–3538. [CrossRef]
53. Bu, H.; Rosdahl, I.; Sun, X.-F.; Zhang, H. Importance of Polymorphisms in NF-KappaB1 and NF-KappaB1alpha Genes for Melanoma Risk, Clinicopathological Features and Tumor Progression in Swedish Melanoma Patients. J. Cancer Res. Clin. Oncol. 2007, 133, 859–866. [CrossRef]

54. Escobar, G.F.; Arraes, J.A.A.; Bakos, L.; Ashton-Prolla, P.; Giugliani, R.; Callegari-Jacques, S.M.; Santos, S.; Bakos, R.M. Polymorphisms in CYP19A1 and NFKB1 Genes Are Associated with Cutaneous Melanoma Risk in Southern Brazilian Patients. Melanoma Res. 2016, 26, 348–353. [CrossRef]

55. Chojnacka, K.; Bilinska, B.; Mruk, D.D. Interleukin 1alpha-Induced Disruption of the Sertoli Cell Cytoskeleton Affects Gap Junctional Communication. Cell. Signal. 2016, 28, 469–480. [CrossRef] [PubMed]

56. Griswold, M.D. The Central Role of Sertoli Cells in Spermatogenesis. Semin. Cell Dev. Biol. 1998, 9, 411–416. [CrossRef] [PubMed]

57. Gutti, R.K.; Tsai-Morris, C.-H.; Dufau, M.L. Gonadotropin-Regulated Testicular Helicase (DDX25), an Essential Regulator of Spermatogenesis, Prevents Testicular Germ Cell Apoptosis. J. Biol. Chem. 2008, 283, 17055–17064. [CrossRef]

58. O’Bryan, M.K.; Hedger, M.P. Inflammatory Networks in the Control of Spermatogenesis: Chronic Inflammation in an Immunologically Privileged Tissue? Adv. Exp. Med. Biol. 2008, 636, 92–114. [CrossRef] [PubMed]

59. Singh, V.; Kumar Mohanty, S.; Verma, P.; Chakraborty, A.; Trivedi, S.; Rajender, S.; Singh, K. XRCC1 Deficiency Correlates with Increased DNA Damage and Male Infertility. Mutat. Res. Toxicol. Environ. Mutagen. 2019, 839, 1–8. [CrossRef]

60. Walter, C.A.; Trolian, D.A.; McFarland, M.B.; Street, K.A.; Gurram, G.R.; McCarrey, J.R. Xrc-1 Expression during Male Meiosis in the Mouse. Biol. Reprod. 1996, 55, 630–635. [CrossRef]